Non-coding RNAs in the Pathogenesis of Alzheimer's Disease: β-amyloid Aggregation, Tau Phosphorylation and Neuroinflammation

Overview

Journal Mol Biol Rep

Date 2025 Jan 31

PMID 39890684

Authors

Irma A Jimenez-Ramirez

Enrique Castano

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder primarily affecting individuals aged 65 and older, characterized by cognitive decline and diminished quality of life. The molecular hallmarks of AD include extracellular β-amyloid plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, and chronic neuroinflammation. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have emerged as potential therapeutic targets due to their regulatory roles in AD pathogenesis. For example, miR-124 has been shown to modulate Aβ levels, while lncRNAs such as BACE1-AS regulate the expression of BACE1, a crucial enzyme in Aβ production. Transcriptomic studies of AD patients have revealed dysregulation of ncRNA expression, further supporting their involvement in disease progression. This review examines the regulatory functions of ncRNAs in AD, focusing on their impact on Aβ, tau hyperphosphorylation, and neuroinflammation. Additionally, we discuss the emerging role of ncRNAs in liquid-liquid phase separation and the formation of protein aggregates, key processes contributing to AD pathology.

References

Scheltens N, Galindo-Garre F, Pijnenburg Y, van der Vlies A, Smits L, Koene T . The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. J Neurol Neurosurg Psychiatry. 2015; 87(3):235-43. DOI: 10.1136/jnnp-2014-309582. View

Hebert L, Bienias J, Aggarwal N, Wilson R, Bennett D, Shah R . Change in risk of Alzheimer disease over time. Neurology. 2010; 75(9):786-91. PMC: 2938969. DOI: 10.1212/WNL.0b013e3181f0754f. View

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

Saunders A, Strittmatter W, Schmechel D, Pericak-Vance M, Joo S, Rosi B . Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993; 43(8):1467-72. DOI: 10.1212/wnl.43.8.1467. View

Pomilio A, Vitale A, Lazarowski A . COVID-19 and Alzheimer's Disease: Neuroinflammation, Oxidative Stress, Ferroptosis, and Mechanisms Involved. Curr Med Chem. 2022; 30(35):3993-4031. DOI: 10.2174/0929867329666221003101548. View

Hebert L, Weuve J, Scherr P, Evans D . Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013; 80(19):1778-83. PMC: 3719424. DOI: 10.1212/WNL.0b013e31828726f5. View

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen C . Alzheimer's disease. Lancet. 2021; 397(10284):1577-1590. PMC: 8354300. DOI: 10.1016/S0140-6736(20)32205-4. View

Spittau B . Aging Microglia-Phenotypes, Functions and Implications for Age-Related Neurodegenerative Diseases. Front Aging Neurosci. 2017; 9:194. PMC: 5469878. DOI: 10.3389/fnagi.2017.00194. View

Weiner H, Frenkel D . Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006; 6(5):404-16. DOI: 10.1038/nri1843. View

10.

Knopman D, Amieva H, Petersen R, Chetelat G, Holtzman D, Hyman B . Alzheimer disease. Nat Rev Dis Primers. 2021; 7(1):33. PMC: 8574196. DOI: 10.1038/s41572-021-00269-y. View

11.

Halle A, Hornung V, Petzold G, Stewart C, Monks B, Reinheckel T . The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008; 9(8):857-65. PMC: 3101478. DOI: 10.1038/ni.1636. View

12.

Thakur S, Dhapola R, Sarma P, Medhi B, Reddy D . Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation. 2022; 46(1):1-17. DOI: 10.1007/s10753-022-01721-1. View

13.

Zhou R, Ji B, Kong Y, Qin L, Ren W, Guan Y . PET Imaging of Neuroinflammation in Alzheimer's Disease. Front Immunol. 2021; 12:739130. PMC: 8481830. DOI: 10.3389/fimmu.2021.739130. View

14.

Yang S, Yang H, Luo Y, Deng X, Zhou Y, Hu B . Long non-coding RNAs in neurodegenerative diseases. Neurochem Int. 2021; 148:105096. DOI: 10.1016/j.neuint.2021.105096. View

15.

Lauretti E, Dabrowski K, Pratico D . The neurobiology of non-coding RNAs and Alzheimer's disease pathogenesis: Pathways, mechanisms and translational opportunities. Ageing Res Rev. 2021; 71:101425. DOI: 10.1016/j.arr.2021.101425. View

16.

Lanzafame M, Bianco G, Terracciano L, Ng C, Piscuoglio S . The Role of Long Non-Coding RNAs in Hepatocarcinogenesis. Int J Mol Sci. 2018; 19(3). PMC: 5877543. DOI: 10.3390/ijms19030682. View

17.

Quinn J, Chang H . Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2015; 17(1):47-62. DOI: 10.1038/nrg.2015.10. View

18.

Cai J, Ni Y, Liu Y . Exploring the Frontier: Antisense Long Non-Coding RNAs as Key Regulators in Alzheimer's Disease. Aging Dis. 2024; . DOI: 10.14336/AD.2024.0762. View

19.

OBrien J, Hayder H, Zayed Y, Peng C . Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018; 9:402. PMC: 6085463. DOI: 10.3389/fendo.2018.00402. View

20.

Yan Y, Yan H, Teng Y, Wang Q, Yang P, Zhang L . Long non-coding RNA 00507/miRNA-181c-5p/TTBK1/MAPT axis regulates tau hyperphosphorylation in Alzheimer's disease. J Gene Med. 2020; 22(12):e3268. DOI: 10.1002/jgm.3268. View